NORRIS MEDICINES LTD.
Latest filings
- Routine compliance certificate on dematerialisation for Q2 FY27 · Compliance
- AGM Results: All 6 Resolutions Passed Including MD Appointment · Board & Shareholder Meetings
- All 6 resolutions passed at Norris Medicines 35th AGM · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and supplies pharmaceutical products, with regulatory clearance to supply the Nigerian market (a clean NAFDAC inspection was completed in December 2025). The operations are run out of Ankleshwar, Gujarat. FY26 revenue from operations was Rs. 813.20 lakhs, up 39.7% from Rs. 582.02 lakhs in FY25, with Q3 FY26 alone delivering Rs. 326.66 lakhs (nearly three times the Rs. 110.60 lakhs in Q3 FY25). The cost base is dominated by materials, which made up 53.4% of FY26 revenue, followed by employee cost at 20.5% and other operating expenses at 18.4%. Despite top-line growth, the company reported a net loss of Rs. 28.06 lakhs for FY26 (improved from Rs. 123.75 lakhs), and operating cash flow was negative at Rs. 11.26 lakhs. Total equity is deeply negative at Rs. -1,514.80 lakhs, and a long-pending Bombay High Court order directing a Rs. 1.33 crore deposit was quashed in November 2025.
Scorecard
Measured from the filed financials, judged against its Trading & Distributors peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from NORRIS MEDICINES LTD.'s filed financials and exchange disclosures
What does NORRIS MEDICINES LTD. do?
NORRIS MEDICINES LTD. is a Commercial Services & Supplies company listed on BSE.
Is NORRIS MEDICINES LTD. profitable?
No. Over the trailing twelve months NORRIS MEDICINES LTD. reported a net loss of ₹0.59 Cr on revenue of ₹9.59 Cr.
Does NORRIS MEDICINES LTD. pay a dividend?
Not in the latest reported year — NORRIS MEDICINES LTD.'s dividend payout for FY26 was nil.
Is NORRIS MEDICINES LTD. debt-free?
No. It reported borrowings of ₹22 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹22 Cr after cash. Its net worth is negative — liabilities exceed assets by ₹15 Cr, so a debt-to-equity ratio is not meaningful.
Is NORRIS MEDICINES LTD. expensive compared with its peers?
On trailing P/E, NORRIS MEDICINES LTD. ranks 21 of 130 in Trading & Distributors — cheaper than 85% of them, against an industry median of 13.9×. This is a position, not a valuation judgement.
How much does the NORRIS MEDICINES LTD. share price move in a day?
On a typical session NORRIS MEDICINES LTD. moves 2.86% — that is the median absolute close-to-close move across its last 265 trading days. MarketPing measures each filing's price reaction against it.
Where can I track NORRIS MEDICINES LTD.'s announcements?
Every NSE and BSE filing by NORRIS MEDICINES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.